articleTop 1% cited
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
The Lancet Oncology · 2014 · Vol. 15(2) · pp. 213–222
Yi‐Long Wu✉(Guangdong General Hospital)Caicun Zhou(Shanghai Pulmonary Hospital)Chengping Hu(Xiangya Hospital Central South University)Jifeng FengShun Lü(Shanghai Jiao Tong University)Yunchao Huang(Kunming Medical University)Wěi Li(First Hospital of Jilin University)Mei Hou(Sichuan University)Jian Hua Shi(Linyi People's Hospital)Kye Young Lee(Konkuk University Medical Center)Chong‐Rui Xu(Guangdong Academy of Medical Sciences)Dan Massey(Boehringer Ingelheim (United Kingdom))Miyoung Kim(Boehringer Ingelheim (South Korea))Yang Shi(Boehringer Ingelheim (China))Sarayut Lucien Geater(Prince of Songkla University)
Lung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesLung Cancer Research StudiesAfatinibMedicineGemcitabineInternal medicineOncologyLung cancerPemetrexedRegimenClinical endpointPopulation
MeSH terms
AfatinibGemcitabineAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungChinaCisplatinDeoxycytidineFemaleHumansLung NeoplasmsMaleMiddle AgedMutationNeoplasm Staging
Citations
1,963
FWCI
164.41
field-weighted impact
References
36
Percentile
100%
vs. same field & year
Citations per year
Cited by
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
The Lancet Oncology · 2015 · 1,573 citations
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2016 · 2,632 citations
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2018 · 2,268 citations
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
The Lancet Oncology · 2017 · 1,350 citations
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Mayo Clinic Proceedings · 2019 · 2,172 citations
References
Interpreting the significance of changes in health-related quality-of-life scores.
Journal of Clinical Oncology · 1998 · 2,890 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Oncogene · 2008 · 1,434 citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · 3,181 citations
The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials
European Journal of Cancer · 1994 · 870 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.